Vanguard Group’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,256,690
| Closed | -$828K | – | 4369 |
|
|
2025
Q2 | $828K | Sell |
2,256,690
-328,530
| -13% | -$110K | ﹤0.01% | 3790 |
|
|
2025
Q1 | $670K | Sell |
2,585,220
-24,825
| -1% | -$14.2K | ﹤0.01% | 3816 |
|
|
2024
Q4 | $1.47M | Sell |
2,610,045
-461,535
| -15% | -$272K | ﹤0.01% | 3649 |
|
|
2024
Q3 | $1.84M | Buy |
3,071,580
+1,154,537
| +60% | +$1.71M | ﹤0.01% | 3583 |
|
|
2024
Q2 | $5.18M | Buy |
1,917,043
+384,998
| +25% | +$1.45M | ﹤0.01% | 3247 |
|
|
2024
Q1 | $7.86M | Buy |
1,532,045
+360,799
| +31% | +$1.17M | ﹤0.01% | 3097 |
|
|
2023
Q4 | $629K | Buy |
1,171,246
+101,441
| +9% | +$53.7K | ﹤0.01% | 3965 |
|
|
2023
Q3 | $709K | Sell |
1,069,805
-5,352
| -0.5% | -$5.41K | ﹤0.01% | 3947 |
|
|
2023
Q2 | $1.63M | Buy |
1,075,157
+619,376
| +136% | +$1.63M | ﹤0.01% | 3729 |
|
|
2023
Q1 | $866K | Buy |
455,781
+122,473
| +37% | +$158K | ﹤0.01% | 3964 |
|
|
2022
Q4 | $317K | Buy |
333,308
+284
| +0.1% | +$288 | ﹤0.01% | 4211 |
|
|
2022
Q3 | $376K | Sell |
333,024
-67,829
| -17% | -$85.4K | ﹤0.01% | 4290 |
|
|
2022
Q2 | $561K | Buy |
400,853
+24,700
| +7% | +$62K | ﹤0.01% | 4261 |
|
|
2022
Q1 | $948K | Sell |
376,153
-4,660
| -1% | -$18.7K | ﹤0.01% | 4225 |
|
|
2021
Q4 | $2.29M | Sell |
380,813
-274,596
| -42% | -$1.9M | ﹤0.01% | 3988 |
|
|
2021
Q3 | $5.11M | Buy |
655,409
+595,409
| +992% | +$6.44M | ﹤0.01% | 3643 |
|
|
2021
Q2 | $814K | Buy |
+60,000
| New | +$742K | ﹤0.01% | 4190 |
|
Other funds holding ELEV
Vanguard Group's ELEV Position: Q3 2025 in Review
Vanguard Group sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 2,256,690 shares — an estimated $828K sold.
Vanguard Group first reported a position in ELEV in Q2 2021 and held it in 17 quarters. The position peaked at $7.86M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Vanguard Group reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Vanguard Group sold 2,256,690 Elevation Oncology shares in Q3 2025, an estimated $828K.
- Vanguard Group first reported a position in Elevation Oncology in Q2 2021 and held it in 17 quarters.
- Vanguard Group's Elevation Oncology position peaked at $7.86M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.